Key result
Randomized trial evaluates alirocumab versus placebo for endothelial-dependent vascular function in healthy volunteers.
RCT (n=30)
Single-blind
1:1
No
Answers are grounded in this paper and cite their sources.
Objective: Whether reducing low density lipoprotein cholesterol (LDL-C) is associated with cardiovascular benefits in low risk normocholesterolaemic subjects is unknown. The INTENSITY LOW [Investigating the lowest threshold of vascular benefits from LDL-cholesterol lowering with a PCSK9 mAb inhibitor (alirocumab) in healthy volunteers] study aims to assess whether lowering LDL-C by alirocumab monotherapy can improve endothelial-dependent vascular function compared with placebo (primary objective) in low-risk normocholesterolaemic healthy individuals. Changes in endothelial-dependent or endothelial-independent vascular function, arterial stiffness and biomarkers of systemic inflammation by alirocumab, atorvastatin or their combination are secondary objectives.Study design and methods: This is a single-center, randomized, two-period, single-blind, placebo-controlled clinical trial. The study was registered on clinicaltrials.gov (N03273972).It will include 30 healthy low-risk subjects with LDL-C < 4.1 mmol/l. After passing the screening visit (Visit 1), eligible participants will be randomized 1:1 to either subcutaneous alirocumab 150 mg or placebo. These will be administered as single doses in 2 visits 14 days apart (Visits 2 and 3). Atorvastatin 20 mg once nightly will be prescribed for 14 days at Visit 3 in both groups through to Visit 4.At baseline (Visit 2) and during all post-dose visits (Visits 3–4), endothelial function will be assessed using venous occlusion plethysmography. Specifically, changes in forearm blood flow responses to intra-arterial infusions of acetylcholine, sodium nitroprusside and L-NG-monomethyl-arginine acetate will be assessed as surrogates of endothelial-dependent and -independent vasodilatation. Additionally, arterial stiffness and carotid intima-media thickness will be evaluated at the same timepoints. The above-mentioned changes will be correlated with changes in lipid and systemic inflammation biomarkers.
No takes yet. Share an insight, caveat, or question.
Kostapanos et al. (2019) conducted an RCT in Normocholesterolaemic healthy low-risk individuals (n=30). Alirocumab (followed by combination with atorvastatin) vs. Placebo (plus atorvastatin 20 mg once nightly for 14 days starting at Visit 3) was evaluated on Endothelial-dependent vascular function assessed by venous occlusion plethysmography. Alirocumab vs placebo will be tested in 30 healthy volunteers with LDL-C < 4.1 mmol/l to assess endothelial-dependent vascular function (study protocol; no results reported).
Synapse has enriched 10 related papers. Consider them for comparative context: